ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-OR066

APOL1 Variants Promote T Cell Excitation by Modulating Calcium (Ca2+) Signaling Downstream of T Cell Receptors (TCRs) in Graft Rejection

Session Information

Category: Transplantation

  • 2101 Transplantation: Basic

Authors

  • Pell, John F., Yale University, New Haven, Connecticut, United States
  • Tanvir, E M, Yale University, New Haven, Connecticut, United States
  • Sun, Zeguo, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Azzi, Jamil R., Harvard Medical School, Boston, Massachusetts, United States
  • Murakami, Naoka, Washington University in St Louis School of Medicine, St. Louis, Missouri, United States
  • Reghuvaran, Anand, Yale University, New Haven, Connecticut, United States
  • Kumar, Ashwani, Yale University, New Haven, Connecticut, United States
  • Barsotti, Gabriel, Yale University, New Haven, Connecticut, United States
  • Ishibe, Shuta, Yale University, New Haven, Connecticut, United States
  • Heeger, Peter S., Cedars-Sinai Medical Center, Los Angeles, California, United States
  • Menon, Madhav C., Yale University, New Haven, Connecticut, United States
Background

Exonic variants in Apolipoprotein-L1 (APOL1-RVs G1 and -G2) increase ESRD-risk vs. the major allele (G0). Multiple data have linked APOL1-RVs in kidney recipients with allograft rejection, but underpinning causal mechanisms are unknown.

Methods

We used BAC-transgenic mice (BAC-Tg) for G0-, G1- or G2-APOL1 expression under the human APOL1 promoter to investigate T-cell phenotype and function, and the CTOT-19 transplant cohort (n=226) to correlate in vivo findings.

Results

Adult G1-BAC-Tg-CD8+T-cells showed more surface APOL1-expression vs G0 and activation, proliferation & central memory (Tcm) expansion after ex-vivo TCR-stimulation, which were reversed with specific APOL1 inhibition (MZ-302). Analogously, APOL1-RVs in CTOT-19 with rejection had increased Tcms pre-transplant (vs G0). In MHC-mismatched cardiac transplants, G1-mice had greater CD8+T-cell infiltration and reduced survival. Bulk RNA-seq of ex-vivo stimulated naïve CD8+T-cells and scRNA-seq of graft infiltrating Tcms showed enrichment of canonical TCR pathways, particularly for Ca2+-signaling. G1-CD8+T-cells had increases in delayed Ca2+ entry with TCR stimulation (+CD3) but reduced early cytosolic Ca2+ entry vs. G0s following addition of Thapsigargin, demonstrating pre-existing ER Ca2+ leak in G1-T-cells, a driver of store-operated calcium entry (SOCE). To test IP3-Ca2+ channel-mediated ER-Ca2+ leak, we inhibited IP3-Ca2+ channels (Xestospongin), observing disproportionate inhibition of proliferation in G1-CD8+T-cells. SOCE inhibition (YM58483) or Ca2+ chelation (BAPTA) at low doses abolished increased proliferation observed in G1 mice, confirming the role of Ca2+ signaling in APOL1-mediated CD8+ T-cell activation.

Conclusion

We unravel an excitatory T-cell intrinsic mechanism for APOL1 exonic variants, causally linking them with kidney rejection.

Funding

  • Other U.S. Government Support

Digital Object Identifier (DOI)